PFE Jan 2024 52.500 put
| Previous Close | 7.55 |
| Open | 7.55 |
| Bid | 7.50 |
| Ask | 7.75 |
| Strike | 52.50 |
| Expire Date | 2024-01-19 |
| Day's Range | 7.55 - 7.55 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 753 |
- Editor's PickYahoo Finance Video
Axios sells itself to Cox Enterprises, Carlyle CEO to step down, CVS and Pfizer look to expand
Yahoo Finance's Julie Hyman breaks down leading business headlines today regarding M&A activity and leadership changes.
- Business Wire
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
NEW YORK & SAINT-HERBLAIN, France, August 08, 2022--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.
- Motley Fool
Why BioNTech Was a Sickly Stock on Monday
BioNTech (NASDAQ: BNTX), the out-of-nowhere German biotech that shot to prominence with the coronavirus vaccine it developed with Pfizer (NYSE: PFE), wasn't having a great Monday. For its second quarter, BioNTech's revenue was just under 3.2 billion euros, or $3.3 billion, while its net profit stood at 1.67 billion euros. In that frame, BioNTech's top line was a bit over 5.3 billion euros, and it netted almost 2.79 billion euros in profit.
